CERo Therapeutics Holdings Inc (NASDAQ: CERO)’s stock price has decreased by -8.94 compared to its previous closing price of 1.02. However, the company has seen a -34.59% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-13 that SOUTH SAN FRANSCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it is presenting encouraging preclinical results of lead compound CER-1236 in ovarian cancer during the 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors in San Diego, March 12-14.
Is It Worth Investing in CERo Therapeutics Holdings Inc (NASDAQ: CERO) Right Now?
Additionally, the 36-month beta value for CERO is 0.60.
The public float for CERO is 2.44M and currently, short sellers hold a 12.00% ratio of that float. The average trading volume of CERO on March 18, 2025 was 754.78K shares.
CERO’s Market Performance
CERO’s stock has seen a -34.59% decrease for the week, with a -48.40% drop in the past month and a -87.78% fall in the past quarter. The volatility ratio for the week is 16.86%, and the volatility levels for the past 30 days are at 13.11% for CERo Therapeutics Holdings Inc The simple moving average for the last 20 days is -37.84% for CERO stock, with a simple moving average of -94.03% for the last 200 days.
CERO Trading at -57.75% from the 50-Day Moving Average
After a stumble in the market that brought CERO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.75% of loss for the given period.
Volatility was left at 13.11%, however, over the last 30 days, the volatility rate increased by 16.86%, as shares sank -54.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -84.52% lower at present.
During the last 5 trading sessions, CERO fell by -34.59%, which changed the moving average for the period of 200-days by -99.12% in comparison to the 20-day moving average, which settled at $1.4942. In addition, CERo Therapeutics Holdings Inc saw -84.52% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CERO starting from YK Bioventures Opportunities G, who sale 2,998,908 shares at the price of $0.06 back on Dec 13 ’24. After this action, YK Bioventures Opportunities G now owns 13,005,169 shares of CERo Therapeutics Holdings Inc, valued at $179,934 using the latest closing price.
YK Bioventures Opportunities G, the 10% Owner of CERo Therapeutics Holdings Inc, sale 1,614,541 shares at $0.07 during a trade that took place back on Dec 12 ’24, which means that YK Bioventures Opportunities G is holding 16,004,077 shares at $113,018 based on the most recent closing price.
Stock Fundamentals for CERO
The total capital return value is set at 4.94. Equity return is now at value -4090.08, with -108.70 for asset returns.
Based on CERo Therapeutics Holdings Inc (CERO), the company’s capital structure generated -0.95 points at debt to capital in total, while cash flow to debt ratio is standing at -5.61. The debt to equity ratio resting at -0.49. The interest coverage ratio of the stock is -543.93.
Currently, EBITDA for the company is -2.44 million with net debt to EBITDA at 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.39.
Conclusion
In conclusion, CERo Therapeutics Holdings Inc (CERO) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
